Kirk JD - Chinook Therapeutics Sr Counsel

KDNYDelisted Stock  USD 39.25  0.20  0.51%   

Insider

Kirk JD is Sr Counsel of Chinook Therapeutics
Phone206 485 7241
Webhttps://www.chinooktx.com

Chinook Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.2682) % which means that it has lost $0.2682 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5685) %, meaning that it created substantial loss on money invested by shareholders. Chinook Therapeutics' management efficiency ratios could be used to measure how well Chinook Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Chinook Therapeutics currently holds 39.44 M in liabilities with Debt to Equity (D/E) ratio of 0.08, which may suggest the company is not taking enough advantage from borrowing. Chinook Therapeutics has a current ratio of 12.35, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Chinook Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Charles IIDay One Biopharmaceuticals
47
Lara MeisnerViridian Therapeutics
50
John NussVentyx Biosciences
66
Kevan ShokatRevolution Medicines
N/A
David PomplianoRevolution Medicines
N/A
Karen AldereteVaxcyte
N/A
Marvin CaruthersViridian Therapeutics
85
Marc MDKura Oncology
50
John McKuneKalvista Pharmaceuticals
48
Neeraj TeotiaArcellx
50
Darlene NociNuvalent
47
David TiceArcellx
53
Noah MDTravere Therapeutics
57
Michael FischbachRevolution Medicines
44
Craig MuirPliant Therapeutics
N/A
Mike PreighDay One Biopharmaceuticals
N/A
Margaret JDRevolution Medicines
62
MBA MBAVaxcyte
63
Stephen MDKura Oncology
53
Kevin CappsCrinetics Pharmaceuticals
N/A
James MDSpringWorks Therapeutics
65
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. Chinook Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 138 people. Chinook Therapeutics (KDNY) is traded on NASDAQ Exchange in USA and employs 214 people.

Management Performance

Chinook Therapeutics Leadership Team

Elected by the shareholders, the Chinook Therapeutics' board of directors comprises two types of representatives: Chinook Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chinook. The board's role is to monitor Chinook Therapeutics' management team and ensure that shareholders' interests are well served. Chinook Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chinook Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Tom Frohlich, Chief Officer
Jodi Jamieson, VP HR
MS MD, Sr Strategy
Eric MBA, Chief Officer
Kirk JD, Sr Counsel
Alan MD, Ex Officer
Andrew DVM, Chief Officer
Eric JD, CEO Pres
Noopur Liffick, VP Communications
Delphine Imbert, VP Operations

Chinook Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chinook Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Other Consideration for investing in Chinook Stock

If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance